Utama › Mieloma Pelbagai › Wilayah Columbia › Washington
Kajian klinikal Mieloma Pelbagai di Washington, DC
22 kajian untuk Mieloma Pelbagai sedang mencari peserta di lokasi dalam dan sekitar Washington (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Mengambil pesertaFasa 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Mengambil pesertaFasa 3
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Mengambil pesertaKajian pemerhatian
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Mengambil pesertaFasa 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Tissue Collection for Studies of Lymph Cancer
Mengambil pesertaKajian pemerhatian
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Mengambil pesertaFasa 4
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi jauh
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Mengambil pesertaFasa 3
- Center for Cancer and Blood Disorders, Bethesda · 7 mi jauh
18F-Fluciclovine PET/CT in Multiple Myeloma
Mengambil pesertaFasa 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Mengambil pesertaFasa 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi jauh
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Mengambil pesertaFasa 2
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
Mengambil pesertaKajian pemerhatian
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Mengambil pesertaFasa 3
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Mengambil pesertaFasa 3
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Mengambil pesertaFasa 2
- GSK Investigational Site, Bethesda · 7 mi jauh
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Mengambil pesertaFasa 3
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Mengambil peserta
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Mengambil pesertaFasa 1
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · 7 mi jauh
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Mengambil pesertaFasa 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · 7 mi jauh
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Mengambil pesertaFasa 3
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Mengambil pesertaFasa 3
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Mengambil pesertaFasa 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Kajian Mieloma Pelbagai di bandar lain
- New York City, NY60 kajian
- Boston, MA42 kajian
- Atlanta, GA42 kajian
- Houston, TX38 kajian
- Durham, NC37 kajian
- Nashville, TN32 kajian
- Denver, CO27 kajian
- Rochester, MN24 kajian
- St. Louis, MO24 kajian
- Columbus, OH24 kajian
- Baldwin Park, CA23 kajian
- Edison, NJ22 kajian
Kajian lain di Washington
- Kanser (semua jenis)58 kajian
- Kanser Paru-paru Bukan Sel Kecil55 kajian
- Kanser Payudara46 kajian
- Kanser Metastatik43 kajian
- Kanser Paru-paru41 kajian
- Kanser Prostat38 kajian
- Obesiti33 kajian
- Kanser Kolorektal29 kajian
- Penyakit Kardiovaskular28 kajian
- Kanser Pundi Kencing26 kajian
- Leukemia Mieloid Akut24 kajian
- Kanser Ovari23 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.